A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane
- 31 August 2002
- journal article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 34 (4) , 274-279
- https://doi.org/10.4143/crt.2002.34.4.274
Abstract
Gemcitabine monotherapy is an effective and safe treatment for refractory breast cancer patients heavily treated with the anthracycline and taxane- based regimen.Keywords
This publication has 0 references indexed in Scilit: